The oral absorption of ALCAR is a highly regulated, complex process
SURPASS program Eli Lilly A1C trial 17-25 lb Weight change 15 mg Mean body weight reduction observed in adults with type 2 diabetes on the highest 15 mg dose across SURPASS A1C-focused trials
Suddenly, your weight loss stalls, your appetite returns, and the medication seems ineffective
Patients with limited subcutaneous tissue (BMI under 25) may find 5-6 millimeter needles at 31-gauge sufficient and more comfortable, while those with higher BMI values typically benefit from 8 millimeter lengths at 28-30 gauge
When to contact your provider: Persistent vomiting (more than 12 hours) Severe abdominal pain Signs of pancreatitis (pain radiating to the back, fever, rapid pulse) No weight loss after 8 weeks at the same dose Hypoglycemic symptoms (shakiness, confusion, sweating) if you're on other diabetes medications The 16-week decision point: At 16 weeks (four months), you and your provider should evaluate total weight loss